Inhibition of paracetamol glucuronidation by tyrosine kinase inhibitors

British Journal of Clinical Pharmacology

Volumn 71, Issue 6, 2011, Pages 917-920

  Liu, Yong ^a   Ramírez, Jacqueline ^a   Ratain, Mark J ^a,b,c  

^a Department of Medicine ^*  (United States)

^b Committee on Clinical Pharmacology and Pharmacogenomics ^*  (United States)

^c UNIVERSITY OF CHICAGO   (United States)

Author keywords

Acetaminophen; Inhibition; Paracetamol; Toxicity; Tyrosine kinase inhibitors; UDP glucuronosyltransferase

Indexed keywords

AXITINIB; DASATINIB; ERLOTINIB; GEFITINIB; GLUCURONOSYLTRANSFERASE; GLUCURONOSYLTRANSFERASE 1A9; IMATINIB; LAPATINIB; NILOTINIB; PARACETAMOL; PROTEIN TYROSINE KINASE; SORAFENIB; URIDINE DIPHOSPHATE; VANDETANIB;

ARTICLE; GLUCURONIDATION; HUMAN; LIVER MICROSOME; PRIORITY JOURNAL;

ACETAMINOPHEN; ANALGESICS, NON-NARCOTIC; DRUG INTERACTIONS; GLUCURONIDES; GLUCURONOSYLTRANSFERASE; HUMANS; MICROSOMES, LIVER; PROTEIN KINASE INHIBITORS; PROTEIN-TYROSINE KINASES;

EID: 79955877359     PISSN: 03065251     EISSN: 13652125     Source Type: Journal    
DOI: 10.1111/j.1365-2125.2011.03911.x     Document Type: Article

References (14)

1. Prescott LF. Kinetics and metabolism of paracetamol and phenacetin. Br J Clin Pharmacol 1980; 10 (Suppl. 2): 291S-98S.
2. Court MH, Duan SX, von Moltke LL, Greenblatt DJ, Patten CJ, Miners JO, Mackenzie PI. Interindividual variability in acetaminophen glucuronidation by human liver microsomes: identification of relevant acetaminophen UDP-glucuronosyltransferase isoforms. J Pharmacol Exp Ther 2001; 299: 998-1006.
3. Mutlib AE, Goosen TC, Bauman JN, Williams JA, Kulkarni S, Kostrubsky S. Kinetics of acetaminophen glucuronidation by UDP-glucuronosyltransferases 1A1, 1A6, 1A9 and 2B15. Potential implications in acetaminophen-induced hepatotoxicity. Chem Res Toxicol 2006; 19: 701-9.
4. Kostrubsky SE, Sinclair JF, Strom SC, Wood S, Urda E, Stolz DB, Wen YH, Kulkarni S, Mutlib A. Phenobarbital and phenytoin increased acetaminophen hepatotoxicity due to inhibition of UDP-glucuronosyltransferases in cultured human hepatocytes. Toxicol Sci 2005; 87: 146-55.
5. Arora A, Scholar EM. Role of tyrosine kinase inhibitors in cancer therapy. J Pharmacol Exp Ther 2005; 315: 971-9.
6. Ridruejo E, Cacchione R, Villamil AG, Marciano S, Gadano AC, Mando OG. Imatinib-induced fatal acute liver failure. World J Gastroenterol 2007; 13: 6608-111.
7. Weise AM, Liu CY, Shields AF. Fatal liver failure in a patient on acetaminophen treated with sunitinib malate and levothyroxine. Ann Pharmacother 2009; 43: 761-6.
8. Liu Y, Ramirez J, House L, Ratain MJ. Comparison of the drug-drug interactions potential of erlotinib and gefitinib via inhibition of UDP-glucuronosyltransferases. Drug Metab Dispos 2010; 38: 32-9.
9. Mross K, Steinbild S, Baas F, Gmehling D, Radtke M, Voliotis D, Brendel E, Christensen O, Unger C. Results from an in vitro and a clinical/pharmacological phase I study with the combination irinotecan and sorafenib. Eur J Cancer 2007; 43: 55-63.
10. Alkharfy KM, Frye RF. High-performance liquid chromatographic assay for acetaminophen glucuronide in human liver microsomes. J Chromatogr B Biomed Sci Appl 2001; 753: 303-8.
11. Copeland RA. Enzymes: A Practical Introduction to Structure, Mechanism, and Data Analysis. New York: Wiley-VCH, 2000.
12. de Morais SM, Wells PG. Enhanced acetaminophen toxicity in rats with bilirubin glucuronyl transferase deficiency. Hepatology 1989; 10: 163-7.
13. Uchaipichat V, Mackenzie PI, Elliot DJ, Miners JO. Selectivity of substrate (trifluoperazine) and inhibitor (amitriptyline, androsterone, canrenoic acid, hecogenin, phenylbutazone, quinidine, quinine, and sulfinpyrazone) 'probes' for human UDP-glucuronosyltransferases. Drug Metab Dispos 2006; 34: 449-56.
14. Miners JO, Attwood J, Birkett DJ. Determinants of acetaminophen metabolism: effect of inducers and inhibitors of drug metabolism on acetaminophen's metabolic pathways. Clin Pharmacol Ther 1984; 35: 480-6.